3M acquires Semfinder to help with rollout of EMR platforms

As conglomerate manufacturing company 3M continues to build up its healthcare records and population analytics platforms, it has acquired Semfinder, a Switzerland-based medical coding technology company.

With $30 billion in sales and 90,000 employees, 3M manufactures products, software platforms and technology for industries ranging from automotive to healthcare and electronics.

The acquisition will provide 3M with coding technology that will help them to accelerate the availability of its 360 Encompass System in countries adopting electronic medical records, the company said in a statement.

“This acquisition builds upon 3M’s expertise in healthcare records coding and applied population analytics serving both providers and payers,” said JaeLynn Williams, vice president and general manager of 3M’s health information systems division, in a statement. “Semfinder’s semantic technology will enable us to accelerate the development of next-generation solutions for healthcare records coding. We look forward to bringing the advantages of the 3M Encompass System to more payers and providers worldwide.”

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.